GPC Biotech Reports that Marketing Authorization Application for Satraplatin is to be Withdrawn

29-Jul-2008

GPC Biotech AG reported that the Company has been informed by its partner for satraplatin in Europe that they plan to withdraw the Marketing Authorization Application (MAA) for satraplatin plus prednisone for the treatment of hormone-refractory prostate cancer patients whose prior chemotherapy has failed. This decision was based on a list of outstanding issues received following review by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) of the filing, which indicates that the opinion of the Committee is that the application is currently not approvable based on the information provided.

Bernd R. Seizinger, M.D., Ph.D., Chief Executive Officer of GPC Biotech said: "Although we previously communicated that the approval of the MAA for satraplatin would be challenging, today's outcome is nevertheless disappointing. We are working closely with our partners to determine the next steps regarding the development of satraplatin and continue to focus our other efforts on advancing our RGB-286638 kinase inhibitor into the clinic and exploring various merger and acquisition opportunities."

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances